MexicoTuberculosis profile
Population  2017 129 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2 (2–2.1) 1.6 (1.6–1.6)
Mortality (HIV+TB only) 0.77 (0.56–1) 0.6 (0.44–0.78)
Incidence  (includes HIV+TB) 28 (22–36) 22 (17–28)
Incidence (HIV+TB only) 3.5 (2.7–4.5) 2.7 (2.1–3.5)
Incidence (MDR/RR-TB)** 0.93 (0.68–1.2) 0.72 (0.53–0.93)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 1.6 (0.97–2.1) 9.2 (5.7–13) 11 (7.1–15)
Males 1.5 (0.93–2.1) 16 (10–22) 18 (12–24)
Total 3 (2.2–3.9) 25 (18–32) 28 (22–36)
TB case notifications, 2017  
Total cases notified 23 520
Total new and relapse 22 757
          - % tested with rapid diagnostics at time of diagnosis 2%
          - % with known HIV status 91%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.1 (0.08–0.13)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 2 526 12%
          - on antiretroviral therapy 1 327 53%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  630
(570–700)
Estimated % of TB cases with MDR/RR-TB 2.6% (2.3–3) 11% (9.2–13)  
% notified tested for rifampicin resistance 6% 43% 2 000
MDR/RR-TB cases tested for resistance to second-line drugs   140
Laboratory-confirmed cases MDR/RR-TB: 148, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 205, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 79% 22 193
Previously treated cases, excluding relapse, registered in 2016 52% 676
HIV-positive TB cases registered in 2016 58% 2 487
MDR/RR-TB cases started on second-line treatment in 2015 71% 164
XDR-TB cases started on second-line treatment in 2015 100% 1
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 12
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-08-19 Data: www.who.int/tb/data